# Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)

> **NCT07550920** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 18 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Drug: Retlirafusp alfa
- **DRUG:** Drug: Single-agent Chemotherapy
- **OTHER:** Procedure: Radical Surgery

## Key facts

- **NCT ID:** NCT07550920
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2027-03-30
- **Final completion:** 2028-01-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550920, "Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07550920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*